Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · GLENMARK

GLENMARK PHA

HealthcarePharmaceuticals & Biotechnology₹74929 cr market cap
₹2608.50 ▼ -1.42% today As of 19 Nov 2026
52-week low ₹1840.8052-week high ₹2677.20

-1.2% from the 52-week high · +43.7% above the low

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,556 full-time employees. The firm is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The firm also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The firm has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.

The short version. GLENMARK PHA reported revenue of ₹4,157 crore for Sep 2026, down 31.3% from a year earlier. Net profit was ₹264 crore (down 56.7% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 46.65% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

GLENMARK PHA trades 1.2% below its 52-week high and 43.7% above its 52-week low.

Change over period: —

1M+19.7%
3M+17.8%
6M+11.2%
1Y+43.6%

2 · The business

Is it growing?

Sales, year on year-31.3%

Sep 2026 revenue of ₹4,157 cr.

Profit, year on year-56.7%

Sep 2026 net profit of ₹264 cr.

Net margin6.3%

3.8 pts lower than a year earlier.

3-year growth66.1% profit

Revenue compounded at 9.4% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue41574018377139016047326432563388
Net profit2644830403610475348
Net margin %6.312.0-0.010.310.11.40.110.3
EPS (₹)9.3517.110.014.2921.631.660.1612.33

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue169831332211813129901230510944106419865
Net profit13621047-1502297942970776925
Net margin %8.07.9-12.72.37.78.97.39.4
EPS (₹)48.2637.11-53.2210.5333.3734.3827.532.78

3 · The quality

How well does it turn capital into profit?

Return on equity was 13.0% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %13.011.8-19.13.1
Return on capital %16.215.96.58.5
EBITDA margin %15.915.69.013.8
Net margin %7.87.8-11.92.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.4%9.7%
Profit CAGR66.1%7.0%
Debt to equity0.00
Interest cover10.5x
Current ratio1.77
P/E ratio40.8

4 · The owners

Who holds it, and are they adding?

Promoter holding46.65%

Unchanged over 8 quarters.

Foreign institutions21.51%

Down 2.0 pts over 8 quarters.

Domestic institutions17.64%

Up 3.79 pts over 8 quarters.

Mutual fund schemes243

+50 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter46.6546.6546.6546.6546.6546.6546.6546.650.0
FII23.5123.1620.6220.7319.220.3420.8921.51-2.0
DII13.8514.617.6418.6120.0919.2918.617.64+3.79
Public15.9615.5615.0613.9714.0213.6813.8114.17-1.79

Mutual fund holdings · Oct 2026

243 schemes hold this stock

193 the month before.

  • quant Healthcare Fund9.38% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND5.22% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund5.2% of NAV
  • Bandhan Focused Fund4.94% of NAV
  • Mirae Asset Healthcare Fund4.61% of NAV
  • Invesco India Pharma and Healthcare Fund4.48% of NAV
  • Motilal Oswal Quant Fund4.12% of NAV
  • quant Large & Mid Cap Fund3.94% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for GLENMARK PHA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about GLENMARK PHA

What is the GLENMARK PHA share price?

GLENMARK PHA (GLENMARK) last closed at ₹2,608.50, down 1.42% on the day. Its 52-week range is ₹1,840.80 to ₹2,677.20.

What is the market cap of GLENMARK PHA?

GLENMARK PHA has a market capitalisation of about ₹74,929 crore. Its price-to-earnings ratio is 40.8.

How are GLENMARK PHA's latest results?

GLENMARK PHA reported revenue of ₹4,157 crore for Sep 2026, down 31.3% from a year earlier. Net profit was ₹264 crore (down 56.7% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 46.65% in Sep 2026, up 0.00 points over 8 quarters.

Who owns GLENMARK PHA?

As of Sep 2026, shareholding was: Promoter 46.65%, FII 21.51%, DII 17.64%, Public 14.17%.

How many mutual funds hold GLENMARK PHA?

243 mutual fund schemes held GLENMARK PHA in October 2026. That compares with 193 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 03 Oct 2025 · Interim Dividend - Rs. 2.5
  • 15 Sep 2025 · Final Dividend - Rs. 2.5
  • 13 Sep 2024 · Final Dividend - Rs. 2.5
  • 18 Sep 2023 · Final Dividend - Rs. 2.5
  • 12 Sep 2022 · Final Dividend - Rs. 2.5
  • 08 Sep 2021 · Final Dividend - Rs. 2.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.